RAIN ENHANCEMENT TECHNO-CL A(NASDAQ:RAIN) stock News

RAIN Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Rain Enhancement Technologies Holdco, Inc.

RAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC. RECEIVES AND APPEALS NASDAQ DELISTING NOTICE

2 days ago - By: Rain Enhancement Technologies Holdco, Inc.

RAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC. RECEIVES AND APPEALS NASDAQ DELISTING NOTICE

4 days ago - By: ACCESS Newswire

Rain Enhancement Technologies Announces Fog Mitigation Pilot in Australia

11 days ago - By: Benzinga - Mentions: CRE SGBX AMBI TPIC ...

12 Industrials Stocks Moving In Wednesday's Intraday Session

12 days ago - By: ACCESS Newswire

Rain Enhancement Technologies Strengthens Board of Directors with Appointment of Industry Veterans Bob Reardon and Marc Peperzak

17 days ago - By: ACCESS Newswire

Rain Enhancement Technologies Announces Appointment of Scott Morris as Senior Technical Advisor

2 months ago - By: Benzinga - Mentions: HTCO CREG GLBS SGBX ...

12 Industrials Stocks Moving In Tuesday's After-Market Session

7 months ago - By: Rain Enhancement Technologies Holdco, Inc.

Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer

2 years ago - By: Pathos AI, Inc.

Pathos AI Completes Acquisition of Rain Oncology

2 years ago - By: Kahn Swick & Foti, LLC

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

2 years ago - By: Brodsky & Smith LLC - Mentions: ABBV AZN CERE CNSL ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.

2 years ago - By: Brodsky & Smith LLC - Mentions: ICVX CNSL CERE AZN ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.

2 years ago - By: Kahn Swick & Foti, LLC

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

2 years ago - By: Brodsky & Smith LLC - Mentions: AYX CNSL CERE

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alteryx, Inc. (NYSE – AYX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.

2 years ago - By: Ademi LLP

Shareholder Alert: Ademi LLP investigates whether Rain Oncology Inc. has obtained a Fair Price in its transaction with Pathos

2 years ago - By: Halper Sadeh LLC

RAIN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Rain Oncology Inc. Is Fair to Shareholders

2 years ago - By: Seeking Alpha

Rain Oncology to be acquired by Pathos AI for $1.16 in cash per share (NASDAQ:RAIN)

2 years ago - By: Rain Oncology Inc.

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

2 years ago - By: Rain Oncology Inc.

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

2 years ago - By: Rain Oncology Inc.

RAIN ENHANCEMENT TECHNO-CL A (RAIN) Stock News

RAIN Latest News, Press Relases and Analysis

RAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC. RECEIVES AND APPEALS NASDAQ DELISTING NOTICE

RAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC. RECEIVES AND APPEALS NASDAQ DELISTING NOTICE

Rain Enhancement Technologies Announces Fog Mitigation Pilot in Australia

12 Industrials Stocks Moving In Wednesday's Intraday Session

Rain Enhancement Technologies Strengthens Board of Directors with Appointment of Industry Veterans Bob Reardon and Marc Peperzak

Rain Enhancement Technologies Announces Appointment of Scott Morris as Senior Technical Advisor

12 Industrials Stocks Moving In Tuesday's After-Market Session

Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer

Pathos AI Completes Acquisition of Rain Oncology

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alteryx, Inc. (NYSE – AYX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.

Shareholder Alert: Ademi LLP investigates whether Rain Oncology Inc. has obtained a Fair Price in its transaction with Pathos

RAIN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Rain Oncology Inc. Is Fair to Shareholders

Rain Oncology to be acquired by Pathos AI for $1.16 in cash per share (NASDAQ:RAIN)

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences